Topic

Journal papers: latest medical news

Major trials and papers in NEJM, The Lancet, JAMA and BMJ.

1. Saturday, October 24, 2026

   Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2)

   Source: The Lancet

   In two randomised trials, Novartis's oral BTK inhibitor remibrutinib was superior to teriflunomide in relapsing MS while maintaining a favourable safety profile, per the authors. STAT reports it cut relapse rates by a third versus the standard treatment.

   Why it mattersBTK inhibitors have faced liver-safety scrutiny as a class, so the hepatic safety detail in the full paper matters as much as efficacy for neurologists and drug-safety teams.